Metraipolis › archive › dc_720b1535635e

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with… — Europe PMC PMID:42087741

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42087741
DOI
10.1002/ctm2.70679
License (as archived)
solo-consultazione
Archived
2026-11-02T20:35:28.203Z
SHA-256 of the archived text
a2dd7e8407015df4f7e62777e35dbae3b3492084a5b6ead524dc53216e51cde3
Stable URL of this page
https://metraipolis.com/documento/dc_720b1535635e

How to cite

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with… — Europe PMC PMID:42087741 — Europe PMC (en), https://europepmc.org/article/MED/42087741 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_720b1535635e (Metraipolis archive dc_720b1535635e, sha256 a2dd7e8407015df4f7e62777e35dbae3b3492084a5b6ead524dc53216e51cde3)
BibTeX
@misc{dc720b1535635e,
  title = {Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with… — Europe PMC PMID:42087741},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42087741},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_720b1535635e; sha256 a2dd7e8407015df4f7e62777e35dbae3b3492084a5b6ead524dc53216e51cde3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42087741. Agents can read the archived copy with the MCP tool read_document.